Get the Stockscreener App
122.04
2.36%
2.80
Jazz Pharmaceuticals Plc stock is traded at $122.04, with a volume of 150.49K.
It is up +2.36% in the last 24 hours and up +7.90% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$119.24
Open:
$121.84
24h Volume:
150.49K
Relative Volume:
0.23
Market Cap:
$7.21B
Revenue:
$3.91B
Net Income/Loss:
$394.92M
P/E Ratio:
-77.73
EPS:
-1.57
Net Cash Flow:
$1.02B
1W Performance:
-1.78%
1M Performance:
+7.90%
6M Performance:
+14.11%
1Y Performance:
+3.20%
1-Day Range:
$120.07
$122.19
1-Week Range:
$115.65
$123.19
52-Week Range:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| JAZZ | 122.01 | 7.21B | 3.91B | 394.92M | 1.02B | -1.57 |
| VRTX | 448.48 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.77 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Pacer Advisors Inc. Buys 278,465 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
John G Ullman & Associates Inc. Sells 11,400 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz stock Zymeworks stock gain on FDA nod (JAZZ:NASDAQ) - Seeking Alpha
Zymeworks' Ziihera Wins FDA Approval: First Dual HER2 Cancer Drug Shows 52% Response Rate | ZYME Stock News - StockTitan
JAZZ (Jazz Pharmaceuticals) COGS-to-Revenue : 0.11 (As of Sep. 2024) - GuruFocus.com
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment - Reuters.com
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - JAZZ's Investor Relations
Jazz Pharmaceuticals to Present at Citi's 2024 Global Healthcare Conference | JAZZ Stock News - StockTitan
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? - Yahoo Finance
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment - Insider Monkey
Jazz Pharmaceuticals: High Uncertainty, Low Risk (undefined:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals shares target raised on patient base growth By Investing.com - Investing.com UK
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Victory Capital Management Inc. Has $28.22 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View - MSN
Los Angeles Capital Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers - Smartkarma
KBC Group NV Has $25.44 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Principal Financial Group Inc. Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Idiopathic Hypersomnia Treatment Market will experience - openPR
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? - Yahoo Finance
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Jazz Pharmaceuticals' EVP Neena Patil sells $456,617 in shares By Investing.com - Investing.com Australia
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PT at $175.00 - MarketBeat
Jazz Pharmaceuticals' EVP Neena Patil sells $456,617 in shares - Investing.com
Jazz (JAZZ) Upgraded to Buy: Here's Why - Yahoo Finance
JAZZ or CTLT: Which Is the Better Value Stock Right Now? - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Kovack Advisors Inc. - MarketBeat
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? - Yahoo Finance
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? - Yahoo Finance
American Assets Inc. Invests $557,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2024 - Marketscreener.com
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
28,693 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by CWA Asset Management Group LLC - MarketBeat
Amalgamated Bank Sells 9,681 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Philip James Wealth Mangement LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2024 Earnings Call Transcript - Insider Monkey
Van ECK Associates Corp Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Quarterly 10-Q Report - Quartzy
Jazz Pharma revenues rise 9% in third quarter | Pharmaceutical | The Pharmaletter - The Pharma Letter
Jazz Pharmaceuticals' (JAZZ) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Robeco Institutional Asset Management B.V. Sells 19,161 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Jazz Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Jazz Hits Record Q3 Revenue with Strong Growth in Sleep Portfolio - Sleep Review
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? - Benzinga
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):